BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1761 related articles for article (PubMed ID: 15690333)

  • 1. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image cytometry: an aid for cytological diagnosis of pleural effusions.
    Osterheld MC; Liette C; Anca M
    Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
    Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
    Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
    Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
    Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.
    Warhol MJ; Hickey WF; Corson JM
    Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
    Cakir E; Demirag F; Aydin M; Unsal E
    Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
    Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
    Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
    Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
    Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
    Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
    Kobzik L; Antman KH; Warhol MJ
    Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
    Kobashi Y; Matsushima T; Irei T
    Respirology; 2005 Nov; 10(5):660-5. PubMed ID: 16268922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.